<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805333</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20-GYN-08</org_study_id>
    <nct_id>NCT04805333</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose Escalation of ArtemiCoffee</brief_title>
  <official_title>A Phase 1 Dose Escalation of ArtemiCoffee in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jill M Kolesar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ArtemiLife</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced&#xD;
      ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel.&#xD;
      The primary objective of this study is to determine the recommended phase II dose (RP2D) of&#xD;
      Artemisia annua.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I dose-escalation study of Artemisia annua (Aa) decaffeinated coffee in&#xD;
      patients with advanced ovarian cancer who have completed front-line chemotherapy with&#xD;
      carboplatin and paclitaxel. The primary objective of this study is to determine the&#xD;
      recommended phase II dose (RP2D) of Aa decaf coffee pods. Sequential cohorts of three&#xD;
      patients per cohort will have escalating doses of Aa, starting with one cup per day (450mg)&#xD;
      and with a maximum of 4 cups per day (1800mg). After identifying the RP2D, the study will&#xD;
      evaluate an expansion cohort of 6 patients for further tolerability and secondary endpoints.&#xD;
      The secondary endpoints include: 1) Efficacy as measured by time to tumor progression or&#xD;
      recurrence; 2) the ability of Aa decaf coffee to influence downstream biomarkers of the&#xD;
      NRF2/KEAP1 signaling pathway; and 3) plasma concentrations of artemisinin and&#xD;
      dihydroartemisinin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase II Dose</measure>
    <time_frame>150 days</time_frame>
    <description>This study will determine the recommended phase II dose of Artemisia annua decaffeinated coffee. Once the dose escalation is finished or 12 patients are evaluated for the dose-limiting toxicity (DLT), the final recommended phase II dose will be determined by isotonic regression to pool the DLT information across all dose levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>150 days</time_frame>
    <description>Median progression free survival will be calculated for all groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma concentration of artemisinin.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>The change in plasma concentration of artemisinin will be measured pre- and post-study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma concentration of dihydroartemisinin.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>The change in plasma concentration of dihydroartemisinin will be measured pre- and post-study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in NQ01 expression.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>Change in cell-free (cfRNA) levels of NQ01 (NAD(P)H:quinone oxidoreductase 1) will be measured at baseline and post-treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HO-1 expression.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>Change in cell-free (cfRNA) levels of HO1 (heme oxygenase 1) will be measured at baseline and post-treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ABCF2 expression.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>Change in cell-free (cfRNA) levels of HO1 (ATP-binding cassette sub-family F member 2) will be measured at baseline and post-treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in CD99 expression.</measure>
    <time_frame>Up to 150 days (baseline and post-treatment)</time_frame>
    <description>Change in cell-free (cfRNA) levels of CD99 (ATP-binding cassette sub-family F member 2) will be measured at baseline and post-treatment.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dose 1 - 450mg Artemisia annua</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 - 900mg Artemisia annua</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 - 1350mg Artemisia annua</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 - 1800mg Artemisia annua</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion - Recommended Phase II Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia annua 450mg</intervention_name>
    <description>Artemisia annua will be self-administered via a preparation of decaffeinated coffee.</description>
    <arm_group_label>Dose 1 - 450mg Artemisia annua</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia annua 900mg</intervention_name>
    <description>Artemisia annua will be self-administered via a preparation of decaffeinated coffee.</description>
    <arm_group_label>Dose 2 - 900mg Artemisia annua</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia annua 1350mg</intervention_name>
    <description>Artemisia annua will be self-administered via a preparation of decaffeinated coffee.</description>
    <arm_group_label>Dose 3 - 1350mg Artemisia annua</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia annua 1800mg</intervention_name>
    <description>Artemisia annua will be self-administered via a preparation of decaffeinated coffee.</description>
    <arm_group_label>Dose 5 - 1800mg Artemisia annua</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemisia annua - recommended phase II dose</intervention_name>
    <description>Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.</description>
    <arm_group_label>Dose Expansion - Recommended Phase II Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and willing to sign a written informed consent document.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Patients diagnosed with Stage II-IV ovarian cancer who have completed initial&#xD;
             first-line therapy with carboplatin and paclitaxel and achieved a complete response.&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN, and AST and ALT ≤ 3.0 x ULN&#xD;
&#xD;
          -  GOG Performance Status ≤ 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study visits, in the opinion of the treating physician.&#xD;
&#xD;
          -  Pregnant women are excluded from this study.&#xD;
&#xD;
          -  Concurrent use of strong inducers of CYP2A6, including phenobarbital and rifampin&#xD;
&#xD;
          -  Women with active gastric ulcers are excluded from this study.&#xD;
&#xD;
          -  Patients who are receiving concurrent maintenance therapy with a PARP inhibitor for a&#xD;
             known hereditary recombinant deficiency (HRD) mutation. Bevacizumab maintenance&#xD;
             therapy is allowed.&#xD;
&#xD;
          -  Concurrent use of nevirapine, ritonavir and strong UGT inhibitors or inducers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Kolesar, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Kolesar, PharmD, MS</last_name>
      <phone>859-323-4978</phone>
      <email>jill.kolesar@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Jill M Kolesar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>dose escalation</keyword>
  <keyword>ArtemiCoffee</keyword>
  <keyword>Artemisia annua</keyword>
  <keyword>ART-Coffee</keyword>
  <keyword>herbal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

